Back to results
US 2020/0346047 A1Published application
Method and kit for home controlled ovarian stimulation for in vitro fertilization
AssigneesZaher Merhi, John Zhang
InventorsZaher Merhi, John Zhang
Life of this patent
Estimating the term…
Abstract
A home controlled ovarian hyperstimulation method for in vitro fertilization (IVF) or egg freezing and a home IVF kit are described herein.
Claims17
1-16. (canceled)
A method for home controlled ovarian stimulation in a female patient in preparation for in vitro fertilization (IVF) or egg freezing, the method comprising the steps of:
- 1) stimulating an increase in the amounts of hormones that support the growth and release of one or more mature eggs in the female patient;
- 2) suppressing luteinizing hormone (LH) release by the pituitary gland by either inserting vaginally in the female patient or administering orally to the female patient a GnRH antagonist in a therapeutically effective amount;
- 3) testing whether the female patient is ovulating using an ovulation predictor kit, wherein if the testing shows the female patient is ovulating, then no further medications are administered to the female patient.
A method for home controlled ovarian stimulation in a female patient in preparation for in vitro fertilization (IVF) or egg freezing, the method comprising the steps of:
- 1) stimulating an increase in the amounts of hormones that support the growth and release of one or more mature eggs in the female patient;
- 2) suppressing luteinizing hormone (LH) release by the pituitary gland by either inserting vaginally in the female patient or administering orally to the female patient a GnRH antagonist in a therapeutically effective amount;
- 3) testing whether the female patient is ovulating using an ovulation predictor kit, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 4;
- 4) administering a leuprorelin or nafarelin nasal spray to the female patient, in a therapeutically effective amount one or more times per day, wherein on the first day of administering the leuprorelin or nafarelin nasal spray to the female patient,
- a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin nasal spray to the female patient, wherein if (a) the testing shows the female patient is ovulating, then no further medications are administered to the female patient, or (b) the testing shows the female patient is not ovulating, then the method proceeds to step 5;
- and
- 5) administering a leuprorelin or nafarelin nasal spray to the female patient in a therapeutically effective amount one or more times per day for a second day, wherein on the second day of administering the leuprorelin or nafarelin nasal spray to the female patient,
- a. testing whether the female patient is ovulating using an ovulation predictor kit each time before administering the leuprorelin nasal spray to the female patient, wherein if the testing shows the female patient is ovulating, then the controlled ovarian stimulation is successful.
5 more elements
Dependencies are inferred from the claim text.